Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The Indian Ministry of Health & Family Welfare has identified 219 districts across the country as priority for intensified interventions for HIV/AIDS, as part of its strategy to control the epidemic by 2027.

The country aims to achieve HIV control by December 1, 2027. As part of its Mission AIDS Suraksha, the Ministry convened the regional workshops titled ‘Suraksha Sankalp Karyashala' in Delhi today.

The workshop laid a special focus on the states of Haryana and Delhi, to chart a targeted approach for program implementation and close monitoring of high-burden districts -- 11 in Haryana and 7 in Delhi.

In Delhi, the identified districts include North, New Delhi, Shahdara, Central, South East, South, and North West. In Haryana, the prioritized districts comprise Panipat, Rohtak, Sirsa, Jhajjar, Gurugram, Faridabad, Bhiwani, Hisar, Sonipat, Kaithal, and Fatehabad.

District program teams from these priority areas presented their progress, shared operational challenges, and collaboratively developed targeted, outcome-oriented action plans to further strengthen the HIV response at the grassroots level.

HIV Status In Delhi And Haryana

As per data from the Ministry, an estimated 59,079 people live with HIV in Delhi, with an adult HIV prevalence of 0.33 percent.

On the other hand, Haryana has an adult HIV prevalence of 0.24 percent, with an estimated 59,642 people living with HIV.

"Delhi continues to face critical gaps, with only around 70 percent of identified individuals currently linked to or receiving treatment, highlighting the urgent need to accelerate treatment coverage and retention,” said Dr. Rakesh Gupta, Additional Secretary & Director General, NACO.

"In contrast, Haryana has achieved a cascade of approximately 81:83:95, reflecting encouraging progress, while also signaling the need for intensified efforts to improve diagnosis and treatment linkage,” he added.

Focus Areas

HIV/AIDS A Public Health Challenge

By 2025, HIV targets were to ensure 95 percent people know their HIV status, 95 percent of them are on lifesaving antiretroviral therapy, and 95 percent of those on treatment are virally suppressed.

As per the National AIDS Control Organization’s report (Sankalak 2024), 81 percent of 25.44 lakh people living with HIV knew their status, 88 percent of them were receiving lifesaving antiretroviral therapy, and 97 percent of those on the treatment were virally suppressed till March 2024.

"HIV/AIDS continues to pose a significant public health challenge, necessitating sustained vigilance, innovation, and coordinated action across all tiers of governance,” said Dr. Gupta, in his keynote address.

Also read: Years After PrEP Rollout, The HIV Prevention Drug Still Remains A Privilege In India

Eliminating Vertical Transmission Of HIV

Dr. Gupta also emphazised the critical importance of eliminating mother-to-child transmission of HIV, which can occur during pregnancy, childbirth, and breastfeeding.

"Such transmission is entirely preventable through timely testing, counselling, and treatment, and called for strengthened antenatal screening and universal access to prevention services to ensure that no child is born with HIV," he added.

Also read: Reducing Mother-To-Child HIV Transmission To Zero Key To End AIDS In India: Experts

Stressing the need for a whole-of-system approach, Dr. Gupta called upon stakeholders across national, state, and district levels to work in close synergy, particularly at the field level, to bridge existing gaps in awareness, testing, treatment, and adherence.

The Suraksha Sankalp Karyashala serves as a vital platform for collaborative planning between national, State, and district stakeholders, reinforcing India’s coordinated, evidence-based, and data-driven approach to HIV prevention and testing services.

It aims to improve linkage and retention on treatment, enhance viral load suppression among people living with HIV, and expand targeted outreach among vulnerable and key populations.

Harish Rana, the 32-year-old resident from Ghaziabad who had been in vegetative condition for the last 13 years has now been removed from ventilators and other life support systems. He has been shifted to a normal bed. As per news reports, his water tube too was removed and a cap was placed on his feeding tube.

As per the hospital sources, Harish Rana's condition is now stable. Following the Supreme Court's order, the medical board will monitor his condition. While his feeding tube has been removed, doctors are still administering brain-soothing medicines.

Harish Rana's parents are also staying with him in AIIMS Delhi. His parents and brothers have been receiving daily counselling.

AIIMS Delhi Is Prepared For India's First Passive Euthanasia

Harish Rana's case marks India's first passive euthanasia. To conduct the passive euthanasia, AIIMS Delhi has set up a specialized team headed by professor and head of the department of anesthesia and palliative medicine, Dr Seema Mishra, has been constituted to implement the process. The team comprises doctors from departments of neurosurgery, onco-anesthesia, and palliative medicine, and psychiatry.

Read: AIIMS Delhi Sets Up Team To Process India's First Ever Passive Euthanasia For Harish Rana

“The process generally involves withholding or withdrawing the nutritional support gradually while ensuring adequate pain relief. The patient is given palliative sedation so that he or she is not in distress. Life support measures such as artificial nutrition, oxygen and medications are slowly withdrawn. The aim is not to prolong nor hasten death,” Dr Sushma Bhatnagar, former head of the department of onco-anaesthesia, pain and palliative care, AIIMS-Delhi.

What Happened To Harish Rana?

It was in 2013 when he suffered severe head injuries after he fell from the fourth floor from his PG accommodation while he was studying at Panjab University. He had been bedridden ever since, and survived on feeding tube. His father filed a petition seeking passive euthanasia under the guidelines Supreme Court had laid down in 2018 under Common Cause judgment. This is the second time the parents have approached the apex court.

In 2024, the court also suggested that Rana could receive home-based care with support from the Uttar Pradesh government. The home-based care includes periodic visits by doctors and physiotherapists. The court suggested that in case home care was not feasible, he could be moved to Noida's district hospital. However, his parents have noted that his condition continued to worsen. Family advocate Rashmi Nandakumar also informed the bench that "nothing seems to be working out".

"He is falling ill quite often and is repeatedly admitted to hospital," she said. The advocate further added that the family only sought passive euthanasia, which is withdrawal of treatment, and not any active intervention.

Justice Pardiwala also read medical reports and observed, "Just look at the condition of the boy. It's pathetic."

Recent court ruling on this case involves a bench comprising Justice JB Pardiwala and Justice KV Viswanathan that allowed the withdrawal of life support for Harish Rana, a resident of Ghaziabad, who has been in a coma and kept alive on tubes for breathing and nutrition after sustaining severe head injuries following a fall from a building in 2013 in Chandigarh.

Meningitis outbreak in Kent University that infected a dozen of people have now further infected more people. The total number as of now is 27, as experts say that incubation period of the bacteria may lead to an increase in number of those who are sick. However, health officials, as per The Guardian report, believe that they have contained the fatal outbreak, with "no cases emerging that are not linked to the original cluster of 20".

Read: UK Meningitis Outbreak: 9-month-old Baby Battles For Life In Intensive Care

The bug that causes the infection has been identified as the known strain of meningitis B and MenB vaccines will be offered to 5,000 students living in the University of Kent halls of residence in Cantebury. While several reports claim that parents are rushing to pharmacies to get their children vaccinated, due to which there is a shortage of the MenB vaccines, health secretary, Wes Streeting has denied any such claims. "There is actually plenty of stock of vaccine supply in the country," he said.

Read: Meningitis Outbreak From Kent University Is Now A National Incident, Parents Fighting For Jabs Amid Low Stock

As per the UK Health Security Agency (UKHSA) official, people infected in Kent were the ones who visited a nightclub on 5,6 or 7 March. The officials, including NHS members and county council public health staff who have been tackling the outbreak believe that it has not been passed on to anyone outside the area. "All cases to date are linked to the current outbreak in Kent," said a UKHSA spokesperson, as reported by The Guardian.

Another official involved in the multi-agency response said, "We may have contained it. There are no cases popping up elsewhere that we know of – no cases that we know of outside the cluster – or not yet anyway. We are rolling out a vaccine and antibiotics and tracing contacts. So there’s nothing we’re not doing.”

Quickest-growing Meningitis Outbreak Ever

UKHSA chief executive Susan Hopkins said the outbreak "looks like a super-spreader" event with "ongoing spread" through universities' halls of residence. She added: "There will have been some parties particularly around this, so there will have been lots of social mixing. I can't yet say where the initial infection came from, how it's got into this cohort, and why it's created such an explosive amount of infections."

She further said that in her 35 years working in medicine, healthcare, and hospitals, "This is the most cases I've ever seen in a single weekend with this type of infection". She added: "It is the explosive nature that is unprecedented here - the number of cases in such a short space of time." She also remarked that this was the "quickest-growing outbreak" she has ever seen in her career.

What Is Meningitis?

Meningitis is a serious medical condition that affects the protective membranes covering the brain and spinal cord, the meninges. While fever is not always present, it is usually considered as one of the classic symptoms of meningitis. It is important to know the varied symptoms, causes, and treatments of meningitis for early diagnosis and proper management of the disease.

Meningitis is an infectious illness that brings about inflammation in the meninges. The most common cause of such inflammation is bacterial or viral infections, though other causes are also possible including fungal, parasitic, or non-infectious causes (autoimmune disease, head injury, or brain surgery). Meningitis may be caused by bacterial meningitis, which the Centers for Disease Control and Prevention (CDC) indicates can be so severe and bring about conditions like hearing loss, vision problems, and death if not received on time.